Published in Arch Dermatol on December 01, 1995
Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol (2013) 3.49
Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients. PLoS One (2013) 1.15
Acral lesions in tuberous sclerosis complex: insights into pathogenesis. J Am Acad Dermatol (2010) 1.13
Tuberous sclerosis complex: neonatal deaths in three of four children of consanguineous, non-expressing parents. J Med Genet (1997) 0.88
Tuberous sclerosis. The persistent challenge of clinical diagnosis. Arch Dermatol (1995) 0.79
Controlled study of malathion and d-phenothrin lotions for Pediculus humanus var capitis-infested schoolchildren. Lancet (1995) 4.16
SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol (2000) 3.06
Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol (2003) 2.92
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet (1998) 2.89
Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol (1995) 2.16
Reducing unnecessary laboratory use with new test request form: example of tumour markers. Lancet (1993) 2.08
Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol (2001) 2.04
Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol (1992) 2.01
Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol (1995) 1.98
The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol (1987) 1.69
Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology (2005) 1.65
Primary cutaneous pleomorphic small T-cell lymphoma. A review of 11 cases. The French Study Group on Cutaneous Lymphomas. Arch Dermatol (1995) 1.64
Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol (1987) 1.62
Neurological complications of neurofibromatosis type 1 in adulthood. Brain (1999) 1.58
Pachydermodactyly and atrophia maculosa varioliformis cutis. Dermatology (1995) 1.57
Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol (1994) 1.57
Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch Dermatol (2001) 1.50
[Intraoperative cholangiography as a routine method? A prospective, controlled, randomized study]. Chirurg (1997) 1.50
Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. Arch Dermatol (1996) 1.50
Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol (1987) 1.45
Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol (1995) 1.43
An analysis of two versus three grades for endometrial carcinoma. Gynecol Oncol (1999) 1.42
Increased serum and blister fluid levels of creatine kinase in patients with toxic epidermal necrolysis. Br J Dermatol (1994) 1.42
Infliximab-induced acne: report of two cases. Br J Dermatol (2007) 1.40
[Isotretinoin in danger! So are the dermatologists!]. Ann Dermatol Venereol (2005) 1.40
[Acne scars: epidemiology, physiopathology, clinical features and treatment]. Ann Dermatol Venereol (2006) 1.40
[Mohs' micrographic surgery: history, principles, critical analysis of its efficacy and indications]. Ann Dermatol Venereol (2004) 1.40
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol (2015) 1.39
Hypothermia related to air-fluidized bed. Intensive Care Med (1991) 1.39
[Treatment of dermatofibroma protuberans with fixed Mohs' micrographic surgery]. Ann Dermatol Venereol (2004) 1.38
Comparative analysis of severe aphthosis and Behçet's disease: 104 cases. Dermatology (1999) 1.38
[Medical activity in a emergency outpatient department dermatology]. Ann Dermatol Venereol (2003) 1.38
Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis (1996) 1.34
Symposium on thrombohemorrhagic phenomena. II. Am J Cardiol (1967) 1.28
Severe cutaneous reactions to self-defense sprays. Arch Dermatol (1993) 1.28
Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol (1996) 1.28
Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol (1996) 1.27
Symptoms associated with malignancy of peripheral nerve sheath tumours: a retrospective study of 69 patients with neurofibromatosis 1. Br J Dermatol (2005) 1.23
Acquired immunodeficiency syndrome in France. Lancet (1983) 1.21
Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol (2005) 1.18
Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med (1997) 1.15
Tinea capitis in adults: misdiagnosis or reappearance? Dermatology (1997) 1.10
Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol (1993) 1.09
Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol (1995) 1.09
Study of folate in psoriasis: blood levels, intestinal absorption and cutaneous loss. Br J Dermatol (1973) 1.08
Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol (1990) 1.08
Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol (1998) 1.07
Oral Crohn disease: clinical characteristics and long-term follow-up of 9 cases. Arch Dermatol (1999) 1.06
Drug-induced severe skin reactions. Incidence, management and prevention. Drug Saf (1995) 1.05
Haemolytic streptococcal gangrene and non-steroidal anti-inflammatory drugs. Br Med J (Clin Res Ed) (1985) 1.03
Graft versus host reaction and lichen planus. Br J Dermatol (1975) 1.01
Variability of the lateral femoral cutaneous nerve: An anatomic basis for planning safe surgical approaches. Clin Anat (2010) 1.00
Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases. J Am Acad Dermatol (1992) 0.99
Disseminated parainfluenza infection in a child with severe combined immunodeficiency. Am J Dis Child (1983) 0.98
Intestinal spirochetosis and acquired immunodeficiency syndrome: ultrastructural studies of two cases. Ultrastruct Pathol (1995) 0.98
B cell deletion, anergy, and receptor editing in "knock in" mice targeted with a germline-encoded or somatically mutated anti-DNA heavy chain. J Immunol (1998) 0.98
Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol (2010) 0.97
Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol (1995) 0.97
Minocycline as possible cause of severe and protracted hypersensitivity drug reaction. Arch Dermatol (1995) 0.97
Lichen planus and hepatitis C virus--related chronic active hepatitis. Arch Dermatol (1994) 0.96
Serotonin content of platelets in inflammatory rheumatic diseases. Correlation with clinical activity. Arthritis Rheum (1983) 0.96
No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene (2001) 0.96
Drug-induced linear IgA disease: target antigens are heterogeneous. Br J Dermatol (1997) 0.95
[Neurofibromatosis 1: recommendations for management]. Arch Pediatr (2002) 0.94
Drug-induced toxic epidermal necrolysis. Clin Dermatol (1998) 0.94
Prolidase deficiency: a multisystemic hereditary disorder. J Am Acad Dermatol (1993) 0.93
Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. Dermatology (2008) 0.93
Pemphigus foliaceus in young women. An endemic focus in the Sousse area of Tunisia. Arch Dermatol (1993) 0.93
Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol (1992) 0.92
What causes hidradenitis suppurativa? Exp Dermatol (2008) 0.92
Internal involvement in localized scleroderma. Medicine (Baltimore) (1994) 0.92
Necrotizing myopathy with pipestem capillaries and minimal cellular infiltration: a case associated with cutaneous signs of dermatomyositis. Neurology (1996) 0.91
Association of porphyria cutanea tarda and lichen planus in a patient with chronic hepatitis C virus infection. Br J Dermatol (1995) 0.91
[Hypereosinophilic syndrome with pachyderma preceding lymphoma. Treatment with interferon alpha]. Ann Dermatol Venereol (1991) 0.91
Longitudinal assessment of children with enteroviral meningitis during the first three months of life. Pediatrics (1981) 0.91
Pheochromocytoma and abdominal paraganglioma. J Visc Surg (2011) 0.91
Evolving pattern of drug-induced toxic epidermal necrolysis. Dermatology (1993) 0.91
[Mückle-Wells syndrome. 5th familial case]. Nouv Presse Med (1972) 0.89
Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol (2001) 0.89
Toxic epidermal necrolysis. Dermatol Clin (2000) 0.89
Carbon dioxide laser for removal of multiple cutaneous neurofibromas. Br J Dermatol (2001) 0.88
Treatment of toxic epidermal necrolysis. Créteil's experience. Arch Dermatol (1987) 0.88
[Fatal epidermoid carcinoma in hidradenitis suppurativa following treatment with infliximab]. Ann Dermatol Venereol (2006) 0.87
[Neurofibromatosis 1: recommendations for management]. Ann Dermatol Venereol (2001) 0.87
Toxic epidermal necrolysis after fluvoxamine. Lancet (1993) 0.87
Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol (1998) 0.87
Development and evaluation of a Global Acne Severity Scale (GEA Scale) suitable for France and Europe. J Eur Acad Dermatol Venereol (2011) 0.87
A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics (1995) 0.87
Oesophageal involvement in pemphigus vulgaris. Lancet (2000) 0.86
[Melanoma and dysplastic nevus after 8 years of topical Caryolysine]. Ann Dermatol Venereol (1984) 0.86
[Furuncular myiasis]. Ann Dermatol Venereol (2006) 0.85
[Treatment of genital Papillomavirus lesions]. Presse Med (1991) 0.85
Value of fine-needle aspiration in infectious cellulitis. Arch Dermatol (1996) 0.85